The matrix metalloproteinases (MMPs) are a family of zinccontaining endopeptidases that are able to degrade the extracellular matrix and allow angiogenesis and tumor invasion. The vast majority of pituitary tumors are benign and do not metastasize to distant sites, although they may invade locally. The aim of this study was to determine whether expression of the collagenase MMP-9 may play a role in allowing angiogenesis and invasion by different pituitary tumor types. Tumor expression of MMP-9 was investigated using a monoclonal antibody on a series of well-characterized paraffin-embedded sections of pituitary tumors.
macroprolactinomas (P ϭ 0.003) when compared with noninvasive macroprolactinomas or the normal anterior pituitary gland. In addition, although there was no difference in whether MMP-9 was present or not when nonfunctioning adenomas that recurred were compared with those that did not, samples of recurrent tumor at the second presentation were more likely to express MMP-9 (P ϭ 0.01). Pituitary carcinomas were significantly more likely to be MMP-9 positive compared with normal anterior pituitary gland (P ϭ 0.05), but there was no difference from invasive adenomas. Angiogenesis assessed by vascular density was related to MMP-9 expression (P Ͻ 0.05).
In summary, we have shown the presence of MMP-9 expression in some invasive and recurrent pituitary adenomas, and in the majority of pituitary carcinoma. The mechanisms whereby MMP-9 expression influences tumor recurrence and invasiveness, and its association with angiogenesis, remains to be elucidated. However, these observations suggest that a future potential therapeutic strategy for some pituitary tumors may be administration of a synthetic MMP-9 inhibitor. (J Clin Endocrinol Metab 85: 2931-2935) P ITUITARY TUMORS are common incidental findings in approximately 10% of the population, and yet clinically relevant tumors due to either endocrine or mass effects are much less common (1, 2) . Despite the fact that the majority of tumors are benign and do not metastasize, a proportion will become locally invasive, leading to bony destruction and infiltration within the cavernous sinus or elsewhere around the pituitary fossa. The surgical treatment of these invasive tumors is often incomplete, and, therefore, therapy to prevent further tumor growth and/or lower excessive hormone secretion is required. The reasons for these differences in tumor behavior are poorly understood, and there are, at present, no reliable mechanisms for predicting tumor behavior.
The matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases that are able to degrade the extracellular matrix, with each MMP acting on different or overlapping sets of substrate (3, 4) . The activity of the MMPs is balanced by the tissue inhibitors of metalloproteinases (5) (6) (7) (8) . MMP-2 and MMP-9 are both type IV collagenases, which have been shown to be important in tumor invasion in vitro because they are able to break down basement membrane, in particular, degrading collagen IV (6, 9) . Elevated levels of circulating MMP-9 have been demonstrated in patients with breast cancer (10), and MMP-2 and/or MMP-9 release has been associated with tumor invasion and metastasis (11) (12) (13) (14) (15) . Some authors have suggested that altered expression of MMP-9 in addition to MMP-11 characterizes epithelial tumors committed to malignant transformation, possibly relating to underlying genetic events that change the tumor phenotype to invasive (16) .
The secretion of MMP is an important early process allowing both migration of endothelial cells through the extracellular matrix and angiogenesis to occur (17) . In vitro studies have shown that microvascular endothelial cells do not constitutively secrete MMP-9, however, when exposed to an angiogenic stimulus (e.g. tumor necrosis factor ␣), MMP-9 production is up-regulated (18) . Angiogenesis can be inhibited by both endogenous tissue inhibitors of metalloproteinases (19, 20) and administration of synthetic MMP inhibitors (e.g. KB-R7785) (21, 22) . In addition to the permissive effects on angiogenesis, MMP-9 has also been shown to have angiostatin-converting enzyme activity, cleaving plasminogen to angiostatin and, thus, potentially enhancing inhibition of angiogenesis (23) and leading to a "balance" of proangiogenic activity and inhibition (24) .
Tumor invasion of surrounding tissues is characteristic of more aggressive and often malignant tumor behavior. One previous small study demonstrated that three invasive pituitary adenomas showed high MMP-9 activity in contrast to four noninvasive tumors (25) . We have previously shown that microvascular density as a measure of angiogenesis is higher in invasive macroprolactinomas when compared with noninvasive tumors. However, the mechanism whereby pituitary tumors become invasive is poorly understood. The aim of our study was to further investigate the role of MMP-9 expression and the process of pituitary tumor invasion and its relation to angiogenesis.
Materials and Methods

Specimen collection
Fifty-five surgically removed pituitary adenomas and nine pituitary carcinomas (three irradiated) were investigated. There were 5 microprolactinomas, 19 macroprolactinomas, and 31 nonfunctioning pituitary adenomas (NFAs). The nonfunctioning tumors had been removed from unirradiated patients and consisted of 12 nonrecurrent tumors, 7 primary tumors that subsequently recurred, and 12 samples of recurrent NFAs. Nonrecurrent tumors had been followed up for a mean of 133 months. Tumor recurrence was detected on the basis of deterioration in visual fields or increase in tumor mass on pituitary imaging (26) . Tumor invasiveness was defined on the basis of the modified Hardy criteria (27) . Four specimens of normal anterior pituitary gland obtained from surgery for pituitary tumors (3) and autopsy (1) were also studied. The tissue has been fixed in 4% buffered formalin, dehydrated, and embedded in paraffin. Histological examination and immunohistochemistry for anterior pituitary hormones had been performed previously, and, together with the clinical, biological, and radiological data, were used to fully characterize each tumor type. In addition, Ki-67 LI, bcl-2 expression, and microvascular density (as a measure of angiogenesis) had also been previously assessed using ulex europaeus agglutinin I in this cohort of tissue (28) .
Immunohistochemistry
Four-micrometer sections were mounted on aptes (3-aminopropyl triethoxy silane; Sigma, St. Louis, MO)-coated slides, dewaxed, and rehydrated. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide. Microwave pretreatment was performed in sodium citrate buffer (pH 6). Nonspecific primary antibody binding was blocked using FCS at a dilution of 1Ϻ20. The primary antibody MMP-9 (R&D Systems, Inc., Minneapolis, MN) was applied overnight at 4C at a dilution of 1Ϻ50. Negative controls were performed where the primary antibody was replaced by FCS. Positive controls were included with every experiment. After three washes in phosphate buffered saline, biotinylated antimouse secondary antibody (Insight Corp., Bucks., UK) was applied at 1Ϻ200 dilution for 30 min at room temperature, followed by washes. The horseradish peroxidase streptavidin complex (DAKO Biotechnology, Wembley, Middlesex, UK) was applied at a 1Ϻ400 dilution for 30 min. Color development was with metal-enhanced diaminobenzidine (Pierce Chemical Co., Rockford, IL) applied for 15 min. The slides were lightly counterstained with hematoxylin.
In addition, double immunostaining was performed with primary antibodies to MMP-9 and CD68, to detect macrophages, and MMP-9 and PRL (DAKO), to demonstrate anterior pituitary tumor cells. For each double-immunostaining experiment, MMP-9 immunostaining was followed by the second primary antibody. Nonspecific antibody binding was blocked using FCS as above, and then the primary antibody was applied for 60 min, followed by washes as described above. The secondary antibody was antimouse for CD68 and antirabbit for PRL, and both were applied at 1Ϻ200 for 30 min. The APAAP complex (Vector Laboratories, Inc., Burlingame, CA) was then applied for 30 min, followed by washes. Color development was with fast red substrate (Vector Laboratories, Inc.) applied for 20 min. The slides were lightly counterstained with hematoxylin.
Assessment of MMP-9
Each slide was examined by an observer blinded to the diagnosis and reviewed by a second blinded observer. The sections were graded as to whether there was definite positive staining for MMP-9, and, secondly, a semiquantitative grade from 1-4 was attributed to the positive cases according to proportion of positively stained cells (low-density staining, moderate-density staining, dense staining, and very dense staining).
Statistical analysis
The Statgraphics (Manugistics, Rockville, MD) software package was used. ANOVA and 2 (with Yates' correction) tests were used for categorical data analysis. P Ͻ 0.05 was considered to represent statistical significance.
Results
Prolactinomas
Invasive macroprolactinomas were significantly more likely to express MMP-9 than noninvasive macroprolactinomas (P ϭ 0.003) ( Table 1 ). In addition, invasive tumors showed higher-density MMP-9 staining than noninvasive tumors (P Ͻ 0.05) (Fig. 1) . There was no difference between noninvasive tumors and normal pituitary gland in terms of MMP-9 positivity (P ϭ 0.7), or between all macroprolactinomas and microprolactinomas (P ϭ 0.3) ( Table 1) .
There was no relation between MMP-9 expression and the Ki-67 LI or bcl-2 expression, however, the microvascular density was significantly higher in MMP-9-positive tumors (n ϭ 6) compared with MMP-9 negative tumors (n ϭ 7) (P Ͻ 0.05) (Fig. 2) .
Nonfunctioning tumors
There was no difference in whether MMP-9 was present or not when primary tumors that recurred were compared with those that did not (P ϭ 0.16) ( Table 1) . However, the tumors removed when they recurred (i.e. at the second presentation) were more likely to express MMP-9 (P ϭ 0.01). Paired cases of the first presentation and then the recurrent tumor were available for four patients. These showed either negative Invasive refers to the definition of invasiveness according to the modified Hardy criteria. Nonrecurrent NFAs are functionless tumors that have not recurred during follow-up, in contrast to the NFA that subsequently regrew. Recurrent NFAs are specimens of tumor removed at the second presentation of the tumor following initial surgery. Extent of positivity refers to semiquantitative assessment of immunostaining, from low (ϩ) to high (ϩϩϩϩ). The number in parentheses refers to the number of positive cases.
MMP-9 expression in the primary case and positive expression in the recurrent cases (two cases) or increased MMP-9 expression in the recurrent tumor compared with the primary presentation (two cases) ( Table 2) .
Pituitary carcinomas
Pituitary carcinomas were significantly more likely to be MMP-9 positive compared with normal anterior pituitary gland (P ϭ 0.05) ( Table 1 ). There was no difference between MMP-9 positivity in pituitary carcinomas compared with invasive adenomas. MMP-9 expression was often localized adjacent to blood vessels. MMP-9 staining was seen both independently from CD68 and also colocalizing with it, suggesting that it is present both in macrophages and other individual cell types (Fig. 3) . MMP did not colocalize with PRL in prolactinomas.
Discussion
In this study, we have demonstrated that both presence of MMP-9 and also level of expression is related to tumor invasiveness in prolactinomas and that the MMP-9 expression is related to tumor recurrence in NFAs. We have also demonstrated that in contrast to noninvasive tumors and microprolactinomas, pituitary carcinomas are more likely to express MMP-9 than the normal pituitary gland. However, there was no difference from invasive adenomas. These data suggest that MMP-9 expression is related to invasiveness and aggressive tumor behaviour in pituitary tumors and its presence or absence in prolactinomas or level of expression in NFAs may act as a possible marker of tumors that are more likely to invade or regrow.
We have shown that MMP-9 is not expressed by tumor cells in invasive tumors, but that it is found in some macrophages. This is in contrast to the data from Kawamoto et al. (25) , who described the presence of MMP-9 in tumor cells in invasive adenomas, but did not report the evidence on which this statement was made. It was also expressed in some unidentified nontumorous cells, which appeared morphologically like macrophages but were not labeled with CD68. It is possible that these may be folliculostellate cells that are "activated" and behaving in a phagocytic manner (29) . Schecter and Weiner (30) suggested that these cells may play a role in basement membrane breakdown in pituitary tumors and showed the presence of collagenase activity in cells with morphological features of folliculostellate cells. Although MMP-9 is expressed at sites of active tissue remodeling during development, it is expressed mainly by inflammatory cells later (31) . In colorectal tumors, for example, MMP-9 has been reported in macrophages only, in contrast to MMP-2, which was found in tumor epithelium, too (32) .
Angiogenesis was related to MMP-9 expression in pituitary tumors. Microvascular density was higher in MMP-9-positive tumors. It is not known whether the increased angiogenesis acts as a stimulant to MMP-9 expression to allow further endothelial migration, or whether the stimulus to angiogenesis also leads to increased MMP-9 expression and, therefore, potentiates tumor invasion. The gene for MMP-9 has been localized to chromosome 20 (33) , and targeted disruption of the MMP-9 gene in mice leads to reduced angiogenesis, suggesting that MMP-9 may play a role in controlling angiogenesis (34) . A relationship between angiogenesis and basement membrane breakdown has been demonstrated in cartilage, where nitric oxide mediates interleukin 1-induced degradation of the extracellular matrix and subsequent release of basic fibroblast growth factor, which may lead to angiogenesis (35) . There are several ongoing trials of synthetic inhibitors of MMP-9 in metastatic tumors of epithelial origin, and, if successful, this may play a role in pituitary tumor management (22) .
Wild-type p53 has recently been shown to have transactivating activity at the MMP-2 promoter (36). The transcriptional activator ETS-1 has been shown to induce MMP-9 expression and tumor invasiveness (37) , and various neuropeptides including somatostatin, bombesin, and calcitonin induce transactivation of tumor cell MMP-9 expression in breast and prostate cancer cell lines (38) . cAMP-responsive element binding protein binding activity has also been demonstrated at the type IV collagenase promoter, and it is known that cAMP-response element binding protein is regulated by hypoxia (39) and also interacts with the HIF-1 response element involved in angiogenesis (40) and the promoter of the cyclin D1 gene involved in initiating the cell cycle (41) . Thus, several upstream promoters may be activating MMP-9 expression in pituitary tumors.
In conclusion, we have shown that MMP-9 expression is associated with more aggressive tumor behavior in pituitary tumors and that angiogenesis and MMP-9 expression are clearly linked, although the mechanism remains to be elucidated. It is interesting to speculate that the transcriptional activation of the MMP-9 promoter may play a role in linking tumor behavior, invasiveness, and angiogenesis. 
